Intravenous Ixazomib in Pediatric Participants With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LLy)
Condition: Precursor Cell Lymphoblastic Leukemia-lymphoma Intervention: Drug: Ixazomib Sponsor: Millennium Pharmaceuticals, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Leukemia | Lymphoma | Pediatrics | Research